Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.40 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.40 |
| ▸ | DUT | P33316 | 2/20 | 0.39 |
| ▸ | ODC1 | P11926 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5426834 | 0.95 | ADRB2 (0.40) | ADRB2ADRB1ADRB3DUTODC1 | |
| SCHEMBL28538333 | 0.90 | DUT (0.43) | DUT | |
| SCHEMBL1561882 | 0.85 | DUT (0.38) | ADRB2ADRB1ADRB3DUT | |
| SCHEMBL8063404 | 0.85 | DUT (0.43) | DUT | |
| Hydrochloric Acid SCHEMBL4075421 | 0.83 | DUT (0.37) | ADRB2ADRB1ADRB3DUT | |
| SCHEMBL27241092 | 0.82 | DUT (0.42) | DUT | |
| SCHEMBL14245094 | 0.82 | DUT (0.42) | DUT | |
| SCHEMBL9007756 | 0.82 | DUT (0.42) | DUT | |
| SCHEMBL26048168 | 0.82 | DUT (0.37) | DUT | |
| SCHEMBL1038400 | 0.81 | ODC1 (0.42) | DUTODC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2252595-B1 | OXIM DERIVATIVES AS HSP90 INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-03-26 | — | — | EP | disclosed |
| EP-1301472-B1 | OXYGENATED ESTERS OF 4-IODO PHENYLAMINO BENZHYDROXAMIC ACIDS | WARNER LAMBERT CO (US) | 2014-03-26 | — | — | EP | disclosed |
| EP-1301472-B1 | OXYGENATED ESTERS OF 4-IODO PHENYLAMINO BENZHYDROXAMIC ACIDS | WARNER LAMBERT CO (US) | 2014-03-26 | — | — | EP | disclosed |
| US-20120264770-A1 | HSP90 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-18 | — | — | US | disclosed |
| US-8084645-B2 | 4-phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (MEK) inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-12-27 | — | — | US | disclosed |
| US-8084645-B2 | 4-phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (MEK) inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-12-27 | — | — | US | disclosed |
| US-8071766-B2 | HSP90 inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-06 | — | — | US | disclosed |
| US-8071766-B2 | HSP90 inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-06 | — | — | US | disclosed |
| US-20110053873-A1 | HSP90 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-03 | — | — | US | disclosed |
| US-20090305998-A1 | HSP90 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-10 | — | — | US | disclosed |
| US-20070105859-A1 | 4-Phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (mek) inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-05-10 | — | — | US | disclosed |
| EP-1674452-A1 | NOVEL 4-PHENYLAMINO-BENZALDOXIME DERIVATIVE AND USE THEREOF AS MEK INHIBITOR | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2006-06-28 | — | — | EP | disclosed |
| US-6960614-B2 | Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids | WARNER-LAMBERT COMPANY (US) | 2005-11-01 | — | — | US | disclosed |
| US-20050176820-A1 | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids | WARNER-LAMBERT COMPANY | 2005-08-11 | — | — | US | disclosed |
| US-20040054172-A1 | Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids | WARNER-LAMBERT COMPANY | 2004-03-18 | — | — | US | disclosed |
| EP-1301472-A2 | OXYGENATED ESTERS OF 4-IODO PHENYLAMINO BENZHYDROXAMIC ACIDS | WARNER-LAMBERT COMPANY (US) | 2003-04-16 | — | — | EP | disclosed |
| WO-2002006213-A2 | OXYGENATED ESTERS OF 4-IODO PHENYLAMINO BENZHYDROXAMIC ACIDS | WARNER-LAMBERT COMPANY (US) | 2002-01-24 | — | — | WO | disclosed |
| EP-0242482-B1 | Antiviral purine derivatives and process for their preparation | BEECHAM GROUP PLC (GB) | 1995-09-06 | — | — | EP | disclosed |
| US-4965270-A | Viricides | BEECHAM GROUP P.L.C. (GB) | 1990-10-23 | — | — | US | disclosed |
| EP-0242482-A2 | Antiviral purine derivatives and process for their preparation | BEECHAM GROUP PLC (GB) | 1987-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090305998-A1 | HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90B1 | ADRB2 4219/4885ADRB1 3715/4885ADRB3 3892/4885 |
| US-20070105859-A1 | 4-Phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (mek) inhibitors | MAPK9, MAPK4, MAPK1 | ADRB2 1490/4885ADRB1 1484/4885ADRB3 1785/4885 |
| US-20050176820-A1 | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids | CYP4X1, CYP2A7, CYP4B1 | ADRB2 825/4885ADRB1 955/4885ADRB3 546/4885 |
| US-20040054172-A1 | Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids | CYP4X1, ALOX5, HAAO | ADRB2 601/4885ADRB1 822/4885ADRB3 576/4885 |
| US-20120264770-A1 | HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90B1 | ADRB2 4219/4885ADRB1 3715/4885ADRB3 3892/4885 |
| US-20110053873-A1 | HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90B1 | ADRB2 4208/4885ADRB1 3632/4885ADRB3 3883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.